LY4006895

Phase 1Small molecule

Eli Lilly

LY4006895 is one of 2 small molecule programs targeting Alzheimer's Disease (AD). It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alzheimer's Disease (AD)Recruiting

Alzheimer's Disease (AD)Phase 1

Recruiting

Competition

Competitive Landscape

1 competitor in Alzheimer's Disease (AD)

#DrugCompanyPhaseTrials

SPG302

SSpinogenix

Phase 2

1 2

LY4006895

Eli Lilly

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Alzheimer's Disease (AD)

NCT06657768

Clinical

Trials by Indication[1]

Alzheimer's Disease (AD)1 trial

A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)

Recruiting· Eli Lilly logo

Eli Lilly·Phase 1·NCT06657768·128 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for LY4006895. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LY4006895 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LY4006895. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Eli Lilly

LY4006895

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Alzheimer's Disease (AD)1 trial

References

Drug Info

Quick Facts

Related News